Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177052 | 0.89 | S1PR1 (0.64) | PLA2G2APLA2G4AS1PR1ACHES1PR3 | |
| SCHEMBL12269410 | 0.81 | S1PR1 (0.60) | S1PR1S1PR3 | |
| SCHEMBL177374 | 0.77 | S1PR1 (0.44) | S1PR1 | |
| SCHEMBL1602506 | 0.76 | S1PR1 (0.80) | S1PR1S1PR3 | |
| SCHEMBL1601740 | 0.75 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL6616917 | 0.74 | S1PR5 (0.60) | S1PR1MAPT | |
| SCHEMBL24227286 | 0.74 | PLA2G2A (0.97) | PLA2G2APLA2G4AABCB1ABCG2PLA2G10 | |
| SCHEMBL2949408 | 0.73 | S1PR1 (0.55) | S1PR1S1PR3 | |
| SCHEMBL22470305 | 0.70 | POLB (0.57) | MAPT | |
| SCHEMBL12269271 | 0.70 | S1PR1 (0.78) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| EP-2344484-B1 | S1P RECEPTORS MODULATORS AND USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2016-06-08 | — | — | EP | disclosed |
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD. (AU) | 2016-02-11 | — | — | US | disclosed |
| US-9193716-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2015-11-24 | — | — | US | disclosed |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD. (AU) | 2014-03-06 | — | — | US | disclosed |
| US-8592399-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2013-11-26 | — | — | US | disclosed |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD (AU) | 2011-12-29 | — | — | US | disclosed |
| EP-2344484-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010043000-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | S1PR1, S1PR5, S1PR2 | PLA2G2A 200/4885PLA2G4A 127/4885S1PR1 1/4885 |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR5, S1PR2 | PLA2G2A 200/4885PLA2G4A 127/4885S1PR1 1/4885 |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR2, S1PR5 | PLA2G2A 168/4885PLA2G4A 121/4885S1PR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.